Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Anal Cancer

Friday Frontline: June 7, 2019

Alexandra Guadagno

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

FDA Approves Age Expansion of HPV Vaccine

Brielle Urciuoli

The Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), according to Merck, the manufacturer of the HPV vaccine.

Driving Research in Rare Cancers

MIKE HENNESSY, SR.

Research continues to drive the oncology field.

Down to the Almighty Dollar: Socioeconomic Status Can Affect Cancer Outcomes

Katie Kosko

A recent study found that socioeconomic status can play a role in survival for patients with anal cancer.

NCCN Establishes Guidelines for Treating People With HIV and Cancer

Brielle Urciuoli

Treatment of HIV has drastically improved since the 1980s, but many of these individuals are still facing barriers to proper cancer care.

Immunotherapy Treatment Advances in Anal Cancer

Meeri Kim

More personalized approaches are being developed to treat patients with metastatic disease.

Despite Benefits, HPV Vaccination Rates Remain Too Low

Jason Harris

Despite impressive efficacy for the human papillomavirus (HPV) vaccine reducing the prevalence of high-risk oral HPV infections by 88 percent, many young adults still are not getting the vaccine – sparking concern in the health community.

Opdivo Is Promising for Advanced Anal Cancer, Study Shows

Jason Harris

The PD-1 inhibitor, Opdivo, may be a promising option for patients with advanced anal cancer, according to a recent study.

Allie Strickler

From stigma to convenience, there are many reasons why people do not get the HPV vaccine, although it can prevent some types of cancer. Lois Ramondetta, M.D., discusses updated recommendations and hopes for getting more young people vaccinated.

Encouraging Phase 2 Trial Data Seen With Immunotherapy in Metastatic Anal Cancer

Virginia Powers, PhD

Opdivo may be a promising treatment option for patients with squamous cell carcinoma of the anal canal.

Anal Cancer

Sign In